Published in Immunotherapy Weekly, August 31st, 2005
"Infliximab is an effective treatment for Crohn's disease, yet about 30% of patients have a weak or no response. The aim of the study was to determine if the likelihood of a patient achieving complete remission 3 months after treatment with infliximab can be predicted from immunological parameters measured in peripheral blood and inflamed intestinal mucosa before the treatment. Twenty-five patients with Crohn's disease resistant to conventional therapy underwent treatment with infliximab," scientists writing in the journal Hepato-Gastroenterology reported.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly